Gene Therapy
🌏 NMPANMPA news and analysis for pharmaceutical BD, investment, and market access
Unlock global gene therapy market insights. Stay ahead on regulatory approvals, clinical trials, and investment opportunities in this cutting-edge biotech sector.
Showing 1–9 of 9 articles
Quick answer
NovaPharmaNews Gene Therapy hub for NMPA covers 9 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Arrowhead Pharmaceuticals Receives TGA Approval for REDEMPLO (Plozasiran) in Australia for Rare Genetic Disorder
Genprex Receives Israel Patent for Reqorsa Gene Therapy Combined with PD-1 Antibodies in Cancer Treatment
Vivacta Bio Raises $50M+ Series A Funding for GT801 CAR-T Gene Therapy Development
Argo Biopharma Doses First Patient in Phase I Trial of siRNA Therapy BW-50218 for TTR-Related Disease
Anixa Biosciences Lira-cel CAR-T Therapy Shows Positive Survival Data in Ovarian Cancer Phase 1 Trial
Andelyn Biosciences Partners with ENCell to Expand Gene Therapy Manufacturing in Asia-Pacific
Rznomics RZ-001 Shows 61.5% Response Rate in Hepatocellular Carcinoma Trial at AACR 2026
Argo Biopharma Begins Phase II Trials of BW-40202 siRNA Therapy for Rare Kidney Diseases
Gene Expression Analysis Market Reaches $5.93 Billion by 2031, Driving Drug Discovery Innovation
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.